Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Phase 3 Study of 131I Metaiodobenzylguanidine (131I MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High Risk Neuroblastoma (NBL) (IND# 134379)
NCT Number:
NCT03126916
Phase:
III
Protocol Type:
Treatment
Age Group:
Children
Disease Sites:
Brain and Nervous System
Study Objectives:
This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma.
Study Documents
(MUSC NetID required for document access)